Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045

June 3, 2025

Los Angeles, June 3, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, today announced it entered an exclusive, worldwide licensing agreement with the University of California, Los Angeles (UCL

Read More 

Globally Recognized Expert in Rare Autoimmune Neurologic Diseases, Dr. Benjamin Greenberg, Joins Trethera Scientific Advisory Board



May 21, 2025

Los Angeles, May 21, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today the appointment of Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board. Dr. Greenberg will assi

Read More 

Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025



April 22, 2025

Los Angeles, April 22, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces a forthcoming panel discussion and poster presentation at the 7th Annual Los Angeles Bioscience Ecosystem Summ

Read More 

Trethera Treats a Late-Stage, Heavily Pretreated Amyotrophic Lateral Sclerosis (ALS) Patient with TRE-515



March 31, 2025

Los Angeles, March 31, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced clinical results from treating a patient with ALS (amyotrophic lateral sclerosis, also known as Lo

Read More 

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control Immune Cell Activation That Causes Multiple Sclerosis Symptoms in Mice



February 25, 2025

Los Angeles, February 25, 2025 — Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to targeting cancer and autoimmune diseases through first-in-class drugs, announced research results in the peer-reviewed journal Immunology demonstrating that TRE-515 selectively

Read More 